Therapeutic advances in Dravet syndrome: a targeted literature review

References

• Hebbar M, Mefford HC. Recent advances in epilepsy genomics and genetic testing. F1000Res. 2020;9:F1000 Faculty Rev–185.
   Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18–34.e3.
   PubMed Web of Science ®Google Scholar
• Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52:3–9.
   PubMedGoogle Scholar
• Dravet C. How Dravet syndrome became a model for studying childhood genetic epilepsies. Brain. 2012;135:2309–2311.
   PubMed Web of Science ®Google Scholar
• Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52:44–49.
   PubMed Web of Science ®Google Scholar
• Knupp KG, Wirrell EC. Treatment strategies for dravet syndrome. CNS Drugs. 2018;32:335–350.
   PubMed Web of Science ®Google Scholar
• Shmuely S, Sisodiya SM, Gunning WB, et al. Mortality in Dravet syndrome: A review. Epilepsy Behav. 2016;64:69–74.
   PubMed Web of Science ®Google Scholar
• Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015;56:e36–9.
   PubMed Web of Science ®Google Scholar
• Rosander C, Hallbook T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol. 2015;57:628–633.
   PubMed Web of Science ®Google Scholar
• Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet Syndrome in a US Population. Pediatrics. 2015;136:e1310–5.
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52:1476–1482.
   PubMed Web of Science ®Google Scholar
• Lagae L, Brambilla I, Mingorance A, et al. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 2018;60:63–72.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Whittington MD, Kim CH, et al. Assessing the impact of caring for a child with Dravet syndrome: results of a caregiver survey. Epilepsy Behav. 2018;80:152–156.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S, Bast T, et al. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia. 2019;60:1697–1710.
   PubMed Web of Science ®Google Scholar
• Lagae L, Irwin J, Gibson E, et al. Caregiver impact and health service use in high and low severity Dravet syndrome: A multinational cohort study. Seizure. 2019;65:72–79.
   PubMed Web of Science ®Google Scholar
• Whittington MD, Knupp KG, Vanderveen G, et al. The direct and indirect costs of Dravet syndrome. Epilepsy Behav. 2018;80:109–113.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: A prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23:392–403.
   PubMed Web of Science ®Google Scholar
• Cross JH, Caraballo RH, Nabbout R, et al. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019;60:S39–s48.
   PubMed Web of Science ®Google Scholar
• Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol. 2011;53:16–18.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Wolff M, Wiemer-Kruel A, et al. Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature. Epilepsy Behav. 2019;98:88–95.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Nabbout R. Recent advances in the drug treatment of dravet syndrome. CNS Drugs. 2019;33:867–881.
   PubMed Web of Science ®Google Scholar
• de Lange IM, Gunning B, Sonsma ACM, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59:1154–1165.
   PubMed Web of Science ®Google Scholar
• Brigo F, Striano P, Balagura G, et al. Emerging drugs for the treatment of Dravet syndrome. Expert Opin Emerg Drugs. 2018;23:261–269.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Russo E, et al. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Drugs Today (Barc). 2019;55:177–196.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Stiripentol: A Review in Dravet Syndrome. Drugs. 2019;79:1785–1796.
   PubMed Web of Science ®Google Scholar
• Polster T. Individualized treatment approaches: fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav. 2019;91:99–102.
   PubMed Web of Science ®Google Scholar
• Eschbach K, Knupp KG. Stiripentol for the treatment of seizures in Dravet syndrome. Expert Rev Clin Pharmacol. 2019;12:379–388.
   PubMed Web of Science ®Google Scholar
• DIACOMIT. Prescribing Information. [ cited 2020 Mar]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
   Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638–1642.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Diacomit: EPAR - Scientific Discussion. 2009. [cited 2020 Mar]. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/diacomit-epar-scientific-discussion_en.pdf
   Google Scholar
• FDA. DIACOMIT. Clinical Review. [ cited 2020 Mar]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2c207223Orig1s000MedR.pdf
   Google Scholar
• Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59:1705–1717.
   PubMed Web of Science ®Google Scholar
• DIACOMIT. Summary of Product Characteristics. [ cited 2020 Mar]. Available from https://www.medicines.org.uk/emc/product/10300/smpc
   Google Scholar
• Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574–578.
   PubMed Web of Science ®Google Scholar
• Rosati A, Boncristiano A, Doccini V, et al. Long-term efficacy of add-on stiripentol treatment in children, adolescents, and young adults with refractory epilepsies: A single center prospective observational study. Epilepsia. 2019;60:2255–2262.
   PubMed Web of Science ®Google Scholar
• Yildiz EP, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in dravet syndrome. J Child Neurol. 2019;34:33–37.
   PubMed Web of Science ®Google Scholar
• De Liso P, Chemaly N, Laschet J, et al. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study. Epilepsy Res. 2016;125:42–46.
   PubMed Web of Science ®Google Scholar
• Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135:73–79.
   PubMed Web of Science ®Google Scholar
• Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22:10–15.
   PubMed Web of Science ®Google Scholar
• EPIDIOLEX. Prescribing Information. [ cited 2020 Mar]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
   Google Scholar
• European Medicines Agency. Epidyolex. [ cited 2020 Mar]. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex
   Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020. DOI:10.1001/jamaneurol.2020.0073
   Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60:294–302.
   PubMed Web of Science ®Google Scholar
• Martin P, de Witte PAM, Maurice T, et al. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2020;394:2243–2254.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2019;77:300–308.
   Web of Science ®Google Scholar
• FINTEPLA. Prescribing Information. [ cited 2020 Mar]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212102s000lbl.pdf
   Google Scholar
• Lagae L, Sullivan J, Nabbout R, et al. Fenfluramine HCL (Fintepla®) provides long-term clinically meaningful reduction in seizure frequency: results of an open-label extension study. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 3.463. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/555553 and https://www.zogenix.com/wp-content/uploads/2018/12/3.463_AES-Study-1503-Effectiveness.pdf
   Google Scholar
• Sullivan J, Auvin S, Pringsheim M, et al. Long-term (2-year) safety and efficacy of adjunctive ZX008 (fenfluramine hydrochloride oral solution) for dravet syndrome: interim results of an ongoing open-label extension study (4684). Neurology. 2020;94:4684.
   Web of Science ®Google Scholar
• Bishop KI, Gioia G, Isquith PK, et al. Improved everyday executive function with fenfluramine HCL oral solution (Fintepla®): results from a phase 3 study in children and young adults with Dravet syndrome. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 2.454. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/552618 and https://www.zogenix.com/wp-content/uploads/2018/11/2.454-AES-Study-1-BRIEF.pdf
   Google Scholar
• Bishop KI, Isquith PK, Gioia G, et al. Profound reduction in seizure frequency (≥75%) leads to improved everyday executive function: analysis from a phase 3 study of ZX008 (fenfluramine HCL) in children/young adults with Dravet syndrome. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 2.438. Available from [cited 2020 Mar]. https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421880 and https://www.zogenix.com/wp-content/uploads/2019/12/01.-FINAL-52349-AES-BRIEF-Poster-2019-12-03v4.pdf
   Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–588.
   PubMed Web of Science ®Google Scholar
• Lai WW, Pringsheim M, Farfel G, et al. Long-term cardiovascular safety of fenfluramine HCL (Fintepla®) in the treatment of Dravet syndrome: interim analysis of an open-label safety extension study. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 3.453. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/554593 and https://www.zogenix.com/wp-content/uploads/2018/12/3.453_AES_Study-1503-Long-Term-CV.pdf
   Google Scholar
• Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33:1773–1781.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57:11–19.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Farfel GM, et al. A Phase 1, Single-Dose, Open-Label Pharmacokinetic Study to Investigate the Drug-DrugInteraction Potential of ZX008 (Fenfluramine HCl Oral Solution) and Cannabidiol. 73rd American Epilepsy Society Annual Meeting. 2019 Dec [cited 2020 Mar]. Available from: https://www.zogenix.com/wp-content/uploads/2019/12/10_ENCORE-52370-AES-1604-CBD-Poster-2019-12-03v1.pdf
   Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131–1139.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Schoonjans AS, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57:e129–34.
   PubMed Web of Science ®Google Scholar
• Veggiotti P, Burlina A, Coppola G, et al. The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus. Epilepsia. 2011;52:83–89.
   PubMed Web of Science ®Google Scholar
• Youngson NA, Morris MJ, Ballard JWO. The mechanisms mediating the antiepileptic effects of the ketogenic diet, and potential opportunities for improvement with metabolism-altering drugs. Seizure. 2017;52:15–19.
   PubMed Web of Science ®Google Scholar
• Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–89.
   PubMed Web of Science ®Google Scholar
• Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;28:1041–1044.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52:e54–7.
   PubMed Web of Science ®Google Scholar
• Yan N, Xin-Hua W, Lin-Mei Z, et al. Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome. Seizure. 2018;60:144–148.
   PubMed Web of Science ®Google Scholar
• Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52:79–82.
   PubMed Web of Science ®Google Scholar
• Caraballo RH, Cersosimo RO, Sakr D, et al. Ketogenic diet in patients with Dravet syndrome. Epilepsia. 2005;46:1539–1544.
   PubMed Web of Science ®Google Scholar
• Tian X, Chen J, Zhang J, et al. The efficacy of ketogenic diet in 60 Chinese patients with dravet syndrome. Front Neurol. 2019;10:625.
   PubMed Web of Science ®Google Scholar
• Liu F, Peng J, Zhu C, et al. Efficacy of the ketogenic diet in Chinese children with Dravet syndrome: A focus on neuropsychological development. Epilepsy Behav. 2019;92:98–102.
   PubMed Web of Science ®Google Scholar
• Dibue-Adjei M, Fischer I, Steiger HJ, et al. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: A meta-analysis of 68 patients. Seizure. 2017;50:147–152.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: A summary of the fourteenth eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59:1811–1841.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT03650452. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of TAK-935 (OV935) as an adjunctive therapy in pediatric patients with developmental and/or epileptic encephalopathies (ELEKTRA). [ cited 2020 Mar]. Available from https://clinicaltrials.gov/ct2/show/NCT03650452
   Google Scholar
• ClinicalTrials.gov. NCT03635073. A phase 2, prospective, interventional, open-label, multi-site, extension study to assess the long-term safety and tolerability of TAK-935 (OV935) as adjunctive therapy in patients with rare epilepsy (endymion). [ cited 2020 Mar]. Available from https://clinicaltrials.gov/ct2/show/NCT03635073
   Google Scholar
• McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1489–1498.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. NCT02758626. Ataluren for nonsense mutation in CDKL5 and Dravet syndrome. [ cited 2020 Mar]. Available from https://clinicaltrials.gov/ct2/show/NCT02758626
   Google Scholar
• Nicita F, Spalice A, Papetti L, et al. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014;23:36–40.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT01607073. Verapamil as therapy for children and young adults with dravet syndrome. [ cited 2020 Mar]. Available from https://clinicaltrials.gov/ct2/show/NCT01607073
   Google Scholar
• Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140:669–683.
   PubMed Web of Science ®Google Scholar
• Tolete P, Knupp K, Karlovich M, et al. Lorcaserin therapy for severe epilepsy of childhood onset: A case series. Neurology. 2018;91:837–839.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. NCT04069689. Study of safety and pharmacokinetics of oral doses of EPX-100 in healthy subjects. [ cited 2020 Mar]. Available from https://clinicaltrials.gov/ct2/show/NCT04069689
   Google Scholar
• Young AN, Tanenhaus A, Belle A, et al. A GABA-selective AAV vector upregulates endogenous SCN1A expression and reverses multiple phenotypes in a mouse model of Dravet syndrome. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 3.1. [cited 2020 Mar]. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421999
   Google Scholar
• Miller I, Dlugos D, Segal E, et al. From gene replacement to gene regulation: developing a disease-modifying AAV gene therapy vector for SCN1A–positive (SCN1A+) pediatric epilepsy. 73rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 1.091. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421087
   Google Scholar
• Isom LL, Chen C, Han Z, et al. Targeted augmentation of nuclear gene output (TANGO) of SCN1A prevents seizures and SUDEP in a mouse model of Dravet syndrome. 72nd American Epilepsy Society Annual Meeting. 2018 Dec. Abst. 1.051. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500169
   Google Scholar
• Liau G, Christiansen A, Han Z, et al. TANGO oligonucleotides for the treatment of Dravet syndrome: safety, biodistribution, and pharmacology in the non-human primate. 3rd American Epilepsy Society Annual Meeting. 2019 Dec. Abst. 2.195. [cited 2020 Mar]. Available from https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421641
   Google Scholar
• Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia. 2020;61:1082–1089.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Adjunctive cannabidiol in patients with dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34:229–241.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Striano P, et al. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia. 2020;61:1090–1098.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86–91.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.
   PubMed Web of Science ®Google Scholar
• Chin RFM. The outcomes of childhood convulsive status epilepticus. Epilepsy Behav. 2019;101:106286.
   PubMed Web of Science ®Google Scholar
• Pujar S, Scott RC. Long-term outcomes after childhood convulsive status epilepticus. Curr Opin Pediatr. 2019;31:763–768.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Zollner JP, Ansorge S, et al. Burden and epidemiology of status epilepticus in infants, children, and adolescents: A population-based study on German health insurance data. Epilepsia. 2019;60:911–920.
   PubMed Web of Science ®Google Scholar
• Specchio N, Pietrafusa N, Ferretti A, et al. Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome. Epilepsia. 2020;61:831–833.
   Web of Science ®Google Scholar
• Ernst JP, Doose H, Baier WK. Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood. Brain Dev. 1988;10:385–388.
   PubMed Web of Science ®Google Scholar
• Lotte J, Haberlandt E, Neubauer B, et al. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43:17–21.
   PubMed Web of Science ®Google Scholar
• Oguni H, Hayashi K, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35:1140–1145.
   PubMed Web of Science ®Google Scholar
• Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81–86.
   PubMed Web of Science ®Google Scholar
• Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–109.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595–1604.
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Zuberi SM. Dravet syndrome–from epileptic encephalopathy to channelopathy. Epilepsia. 2014;55:979–984.
   PubMed Web of Science ®Google Scholar